Welcome to our dedicated page for Tiziana Life Sciences Com news (Ticker: TLSA), a resource for investors and traders seeking the latest updates and insights on Tiziana Life Sciences Com stock.
Tiziana Life Sciences Ltd. (NASDAQ: TLSA) is a clinical-stage biopharmaceutical company whose news flow centers on the development of intranasal foralumab, a fully human anti-CD3 monoclonal antibody, and related immunomodulation programs. Company announcements highlight progress in neuroinflammatory and neurodegenerative indications, including non-active secondary progressive multiple sclerosis, early Alzheimer’s disease, and amyotrophic lateral sclerosis (ALS).
News about Tiziana often covers key clinical milestones. Recent releases describe dosing of patients in a Phase 2 randomized, placebo-controlled trial of intranasal foralumab in early Alzheimer’s disease, including evaluation as monotherapy and in combination with FDA-approved anti-amyloid therapies lecanemab and donanemab. Other updates report on the Expanded Access Program in non-active secondary progressive multiple sclerosis and the acceptance of the company’s ALS Phase 2 trial into the ALS MyMatch Program at the Sean M. Healey & AMG Center for ALS.
Investors following TLSA news can also expect regulatory and safety updates, such as the submission of Development Safety Update Reports to the U.S. Food and Drug Administration, which summarize cumulative exposure and safety findings for intranasal foralumab. Corporate and capital markets news includes insider share purchases by senior leadership, decisions regarding proposed public offerings, and participation in industry conferences like BIO-Europe, the Jefferies London Healthcare Conference, and neuroscience-focused forums.
This news page aggregates these company-issued press releases and related coverage, giving readers a centralized view of Tiziana’s clinical progress, regulatory interactions, strategic initiatives such as the planned spinout of IL-6 asset TZLS-501, and visibility events like ringing the Nasdaq Closing Bell. Users interested in TLSA can review this feed to monitor how Tiziana’s immunotherapy and drug delivery programs evolve over time.
Tiziana Life Sciences (NASDAQ:TLSA), a biotechnology company focused on immunomodulation therapies, announced that CEO Ivor Elrifi has purchased 193,848 shares of company common stock at $1.65 per share in the open market. The company's lead development candidate is intranasal foralumab, a fully human anti-CD3 monoclonal antibody.
Tiziana Life Sciences (NASDAQ:TLSA), a biotechnology company focused on immunomodulation therapies, announced that its Executive Chairman and Founder Gabriele Cerrone has increased his stake in the company through a share purchase. Cerrone acquired 25,000 common shares at $1.60 per share, bringing his total holdings to 43,277,143 shares, representing 36.28% of the company's issued share capital.
Tiziana Life Sciences (NASDAQ:TLSA) has initiated dosing in its Phase 2a clinical trial of intranasal foralumab for Multiple System Atrophy (MSA) at Brigham and Women's Hospital in Boston. The six-month open-label study will evaluate foralumab's potential to reduce neuroinflammation in MSA patients through a novel nasal delivery system.
MSA is a rare neurodegenerative disorder affecting 15,000-50,000 people in the United States, with no FDA-approved treatments to alter disease progression. The trial (NCT06868628) will involve eight dosing cycles to assess the therapy's ability to slow disease progression and enhance quality of life through regulatory T cell engagement.
Tiziana Life Sciences (NASDAQ:TLSA) has received FDA approval for its Phase 2a Investigational New Drug (IND) application to study intranasal foralumab in Multiple System Atrophy (MSA) patients. The six-month, open-label clinical trial will evaluate foralumab, a fully human anti-CD3 monoclonal antibody, for its effects on microglial activation, clinical outcomes, and safety.
MSA is a rare, rapidly progressive neurodegenerative disorder with no FDA-approved treatments. The disease affects 1.9-4.9 per 100,000 people worldwide, with a median survival of 6-9 years. The trial (NCT06868628) will administer foralumab via nasal spray in eight 3-week dosing cycles, targeting T-cell mediated neuroinflammation.
Tiziana Life Sciences (NASDAQ:TLSA) has reported promising immunologic findings from treating a moderate Alzheimer's Disease patient with intranasal foralumab, their lead immunomodulation therapy. The analysis revealed significant immune modulatory effects in white blood cells, including changes in CD4 cells, CD8 cells, and monocytes.
Key findings include a marked reduction in brain inflammation confirmed by microglia PET scans and an unexpected increase in phagocytosis markers in classical monocytes, suggesting potential for enhanced amyloid plaque clearance. The treatment was well-tolerated with no side effects, and the patient will continue therapy for an additional 6 months.
Tiziana Life Sciences (NASDAQ: TLSA) has showcased promising developments in their intranasal foralumab treatment for moderate Alzheimer's disease through a national radio interview. The treatment, a fully human anti-CD3 monoclonal antibody administered as a nasal spray, targets brain inflammation associated with Alzheimer's progression. Dr. Howard Weiner highlighted remarkable results from the first patient, Joe Walsh, at Brigham and Women's Hospital in Boston. According to Walsh's wife Karen, the treatment has led to noticeable improvements in his social engagement and overall condition. The case represents an encouraging advancement in Alzheimer's treatment, particularly in addressing brain inflammation as a key factor in disease progression.
Tiziana Life Sciences (NASDAQ: TLSA) announced that Executive Chairman and Founder Gabriele Cerrone has increased his stake in the company through the purchase of 15,000 common shares at $1.55 per share. Following this transaction, Cerrone's total holdings have reached 43,252,143 common shares, representing 37.02% of the company's issued share capital. Tiziana is developing immunomodulation therapies, with its lead candidate being intranasal foralumab, a fully human anti-CD3 monoclonal antibody.